Given its central role in tumor progression and resistance to therapy, targeting hypoxia-induced angiogenesis represent an attractive strategy in cancer centered on two molecular targets, HIF-1 and VEGF [44–46]. The gene discussed is HIF1A; the disease is neoplasm.